CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
Rhea-AI Summary
CapsoVision (NASDAQ: CV) announced that senior management will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025 in New York City.
Attending executives include Johnny Wang, President and CEO; David Garcia, SVP Finance; and Doug Atkinson, SVP Global Sales. Investors seeking a one-on-one meeting are asked to contact their Benchmark representative or email Investors@CapsoVision.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CV declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to participate in 1:1 Investor Meetings on December 4, 2025
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on Thursday, December 4, 2025 in New York City.
If you are interested in arranging a one-on-one meeting with CapsoVision’s management team at the conference, please contact your Benchmark representative or reach out to the company directly at Investors@CapsoVision.com.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
When will CapsoVision (CV) management meet investors at the Benchmark Discovery conference?
Which CapsoVision executives will attend the Benchmark 14th Annual Discovery conference?
How can investors arrange a one-on-one meeting with CapsoVision (CV) at the December 4, 2025 conference?
What topics will CapsoVision (CV) management likely cover at the investor meetings on December 4, 2025?
Where is the Benchmark 14th Annual Discovery One-on-One Investor Conference being held for CapsoVision (CV)?
Is there contact information for arranging CapsoVision (CV) investor meetings at the December 4, 2025 event?
